These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 7624448

  • 1. Generation of lymphokine-activated killer (LAK) cell activity from malignant peritoneal effusions.
    Chao TY, Hwang WS, Yeh MY.
    Proc Natl Sci Counc Repub China B; 1995 Apr; 19(2):92-8. PubMed ID: 7624448
    [Abstract] [Full Text] [Related]

  • 2. [Functional and phenotypic analysis of tumor infiltrating lymphocytes derived from solid tumors and effusion associated lymphocytes in malignant ascites cultured in recombinant interleukin 2].
    Itoh K, Shiiba K, Ebina N, Anzai R, Ouchi A, Matsuno S.
    Nihon Geka Gakkai Zasshi; 1993 Aug; 94(8):781-90. PubMed ID: 8377752
    [Abstract] [Full Text] [Related]

  • 3. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP, Blanchard DK, Duan C, Roberts WS, Cavanagh D, DeCesare S, Djeu JY.
    J Soc Gynecol Investig; 1995 Aug; 2(6):762-71. PubMed ID: 9420887
    [Abstract] [Full Text] [Related]

  • 4. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients.
    Chen YM, Yang WK, Ting CC, Tsai WY, Yang DM, Whang-Peng J, Perng RP.
    Chest; 1997 Oct; 112(4):960-6. PubMed ID: 9377959
    [Abstract] [Full Text] [Related]

  • 5. [In vitro experimental expansion and induction of LAK cell of lymphocytes from human carcinomatous ascites].
    Li DJ.
    Zhonghua Zhong Liu Za Zhi; 1989 Nov; 11(6):433-6. PubMed ID: 2634542
    [Abstract] [Full Text] [Related]

  • 6. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 7. Functional and phenotypic characteristics of recombinant interleukin-2 or T-cell growth factor-activated splenic lymphoid cells from patients with gastric or hepatocellular carcinoma.
    Ebihara T, Fukao K, Koyama S.
    Cancer; 1990 Sep 01; 66(5):923-9. PubMed ID: 2167147
    [Abstract] [Full Text] [Related]

  • 8. Soluble HLA class I molecules in malignant pleural and peritoneal effusions and its possible role on NK and LAK cytotoxicity.
    Amirghofran Z, Sheikhi AK, Kumar PV, Saberi Firouzi M.
    J Cancer Res Clin Oncol; 2002 Aug 01; 128(8):443-8. PubMed ID: 12200601
    [Abstract] [Full Text] [Related]

  • 9. [In vitro induction of cytotoxic activity against carcinomatous pleural or peritoneal lymphoid cells cultivated with cytokines, and an immunological phenotypic analysis of the effector cells].
    Ebihara T, Koyama S.
    Gan No Rinsho; 1990 Apr 01; 36(5):604-10. PubMed ID: 2325266
    [Abstract] [Full Text] [Related]

  • 10. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
    McKenzie RS, Simms PE, Helfrich BA, Fisher RI, Ellis TM.
    Cancer Res; 1992 Nov 15; 52(22):6318-22. PubMed ID: 1384959
    [Abstract] [Full Text] [Related]

  • 11. Heterogeneity in lectin-binding characteristics of human lymphokine-activated killer cells.
    Maruyama T, Imai Y, Harada K, Okada T, Takano M, Ikeda Y, Toda G, Oka H, Osawa T.
    J Biol Response Mod; 1990 Aug 15; 9(4):378-86. PubMed ID: 2395003
    [Abstract] [Full Text] [Related]

  • 12. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y, Zighelboim J, Berek JS, Bonavida B.
    Nat Immun Cell Growth Regul; 1990 Aug 15; 9(4):283-96. PubMed ID: 2215516
    [Abstract] [Full Text] [Related]

  • 13. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA, Vujanovic NL, Herberman RB, Hiserodt JC.
    J Immunol; 1988 Apr 15; 140(8):2846-52. PubMed ID: 3258622
    [Abstract] [Full Text] [Related]

  • 14. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells.
    Tilden AB, Itoh K, Balch CM.
    J Immunol; 1987 Feb 15; 138(4):1068-73. PubMed ID: 3100627
    [Abstract] [Full Text] [Related]

  • 15. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K, Yasumoto K, Yano T, Matsuzaki G, Sugimachi K, Nomoto K.
    Cancer Res; 1991 Oct 01; 51(19):5261-5. PubMed ID: 1833049
    [Abstract] [Full Text] [Related]

  • 16. Growth of MCF-7 human breast carcinoma in severe combined immunodeficient mice: growth suppression by recombinant interleukin-2 treatment and role of lymphokine-activated killer cells.
    Zhai YF, Esselman WJ, Oakley CS, Chang CC, Welsch CW.
    Cancer Immunol Immunother; 1992 Oct 01; 35(4):237-45. PubMed ID: 1511458
    [Abstract] [Full Text] [Related]

  • 17. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
    Kikuchi T, Sakai H, Nakamura N, Watanabe M, Ohno T.
    No To Shinkei; 1990 Jun 01; 42(6):575-80. PubMed ID: 2119634
    [Abstract] [Full Text] [Related]

  • 18. [Effect of malignant ascitic fluids and OK-432 on the induction of LAK activity in peripheral blood mononuclear cells of gynecological cancer patients].
    Kanaoka Y, Umesaki N.
    Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun 01; 43(6):611-8. PubMed ID: 1856521
    [Abstract] [Full Text] [Related]

  • 19. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD, Economou JS, Shau H, Golub SH.
    J Surg Res; 1993 Nov 01; 55(5):486-92. PubMed ID: 8231167
    [Abstract] [Full Text] [Related]

  • 20. Differential activation of lymphokine-activated killer cells with different surface phenotypes by cultivation with recombinant interleukin 2 or T-cell growth factor in gastric cancer patients.
    Koyama S, Ebihara T, Fukao K, Osuga T.
    Jpn J Cancer Res; 1989 Feb 01; 80(2):150-7. PubMed ID: 2498249
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.